More recently, Li et al. tested the combination of anti-PD-1 antibodies and different doses of VEGFR2-targeting agents in syngeneic BC mouse models, demonstrating a dose-dependent synergism between antiangiogenic therapy and IC blockade. This evidence concerns the gene KDR and breast cancer.